This prospective cohort study aims to determine whether high-risk coronary plaques identified by novel Photon-Counting Detector CT (PCCT) independently predict future major adverse cardiovascular events (MACE). Participants will be followed for MACE and revascularization. The primary hypothesis is that the incidence of MACE is significantly higher in patients with PCCT-defined high-risk plaque than in those without. Additionally, patients will undergo Optical Coherence Tomography (OCT) and angiography within a month after PCCT; PCCT results will be compared with OCT in a cross-sectional analysis, and diagnostic performance will be evaluated against follow-up data.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years
* Scheduled for clinically indicated, non-emergent invasive coronary angiography
* Provision of written informed consent and willingness to comply with long-term follow-up
Exclusion Criteria:
* Estimated glomerular filtration rate \<45 mL/min/1.73 m²
* Known allergy to iodinated contrast media
* Pregnancy or breastfeeding
* Persistent atrial fibrillation or other arrhythmia precluding adequate ECG-gated CT acquisition
* Body mass index \>40 kg/m²
* Target vessel with a previously implanted stent
* Life expectancy \<2 years or any condition that, in the opinion of the investigator, makes follow-up unlikely or participation inappropriate
Primary outcome measure(s)
Incidence of major adverse cardiovascular events (MACE) — Up to 24 months Incidence of major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction, and hospitalization for unstable angina requiring urgent revascularization, stratified by the presence versus absence of PCCT-defined high-risk plaque.
Trial sites (1)
Facility
City
Region
Status
Beijing Chaoyang Hospital，Capital Medical University, Beijing
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.